大连翔珑生命科技股份有限公司

Dragongen is an innovative enterprise focusing on the international frontier senescent cell removal technology health products and the creation of high-end biological enzymes by synthetic biology and artificial intelligence. In particular, we develop and produce RNA synthase and high-end industrial enzyme series products used in biomedical industry and research, and are committed to providing quality services for basic research in life science, medical research, drug development and production, and in vitro diagnosis. At present, Dragongen is focused on the new drug discovery of anti-aging, anti-tumor natural products and peptide-drug conjugates (PDC), antibody-drug conjugates (ADC) and other drug conjugates , with a unique vision, a new molecular paradigm, to provide the market with a new generation of innovative health care products.
 
Dragongen has built a modern GLP laboratory and a 100,000 grade industrialization pilot laboratory, and is preparing to build a 4,000 square meters enzyme engineering production line and a total quality management system. Dragongen has a scientific research team of more than 100 people, including dozens of senior professional and technical personnel at doctoral and postgraduate levels, and strives to provide the most professional services for excellence and innovation in the industry in the near future.
 
 
大连翔珑生命科技股份有限公司（简称“翔珑生物”）是一家人工智能及合成生物技术创制高端生物酶和衰老细胞清除技术双核驱动的创新型企业，公司秉持 “深耕智慧合成生物，聚焦健康长寿产业”的理念，致力于在五年内发展成为国际一流的高端生物公众公司。公司成立于2024年7月6日，注册资本3000万元人民币。在大连市高新园区和金普新区分别建有现代化的GLP实验室和十万级高洁净度的产业化中试研究室。拥有一支百余人的高素质科研团队，其中包括数十名博士及研究生等高级专业技术人员。公司创新商业模式、聚焦医药大健康和工业需求，拥有明确产业化路径和强大协同创新网络。